Clinical trial
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or…
NCT00003079 · Virginia Commonwealth University, Other · Completed
Key facts
| NCT number | NCT00003079 |
|---|---|
| Title | Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma |
| Official title | Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia |
| Lead sponsor | Virginia Commonwealth University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | bryostatin 1, cytarabine |
| Enrollment | 30 |
| Start date | Sep 1, 1997 |
| Primary completion | May 1, 2001 |
| Completion | May 1, 2001 |
| First posted | May 27, 2004 |
| Last update posted | Feb 17, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: